Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight-Reference-Cited by-同舟云学术

Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight

Published:2024 Issue: Volume:21 Page:100399
ISSN:2213-0489
Container-title:Leukemia Research Reports
language:en
Short-container-title:Leukemia Research Reports

Author:

Ielo Claudia^ORCID,Fazio Francesca,Rocchi Serena,Rizzello Ilaria,Mancuso Katia,Zamagni Elena,Cavo Michele,Petrucci Maria Teresa

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference15 articles.

1. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma;Mateos;Leukemia,2022

2. Anti-BCMA CAR T-cell therapy: changing the natural history of multiple myeloma;Puertas;Hemasphere,2022

3. Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy;Wudhikarn;Bone Marrow Transplant.,2022

4. COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP;Busca;Blood Adv.,2022

5. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma;San-Miguel;N. Engl. J. Med.,2023

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide;Blood Reviews;2024-07

2. Multiple drugs;Reactions Weekly;2024-01-20